Human Relaxin‐2 Fusion Protein Treatment Prevents and Reverses Isoproterenol‐Induced Hypertrophy and Fibrosis in Mouse Heart
Open Access
- 17 December 2019
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Journal of the American Heart Association
- Vol. 8 (24), e013465
- https://doi.org/10.1161/jaha.119.013465
Abstract
Background Heart failure is one of the leading causes of death in Western countries, and there is a need for new therapeutic approaches. Relaxin‐2 is a peptide hormone that mediates pleiotropic cardiovascular effects, including antifibrotic, angiogenic, vasodilatory, antiapoptotic, and anti‐inflammatory effects in vitro and in vivo. Methods and Results We developed RELAX10, a fusion protein composed of human relaxin‐2 hormone and the Fc of a human antibody, to test the hypothesis that extended exposure of the relaxin‐2 peptide could reduce cardiac hypertrophy and fibrosis. RELAX10 demonstrated the same specificity and similar in vitro activity as the relaxin‐2 peptide. The terminal half‐life of RELAX10 was 7 days in mouse and 3.75 days in rat after subcutaneous administration. We evaluated whether treatment with RELAX10 could prevent and reverse isoproterenol‐induced cardiac hypertrophy and fibrosis in mice. Isoproterenol administration in mice resulted in increased cardiac hypertrophy and fibrosis compared with vehicle. Coadministration with RELAX10 significantly attenuated the cardiac hypertrophy and fibrosis compared with untreated animals. Isoproterenol administration significantly increased transforming growth factor β1 (TGF‐β1)–induced fibrotic signaling, which was attenuated by RELAX10. We found that RELAX10 also significantly increased protein kinase B/endothelial NO synthase signaling and protein S‐nitrosylation. In the reversal study, RELAX10‐treated animals showed significantly reduced cardiac hypertrophy and collagen levels. Conclusions These findings support a potential role for RELAX10 in the treatment of heart failure.This publication has 55 references indexed in Scilit:
- Effects of serelaxin in subgroups of patients with acute heart failure: results from RELAX-AHFEuropean Heart Journal, 2013
- Dynamic denitrosylation via S -nitrosoglutathione reductase regulates cardiovascular functionProceedings of the National Academy of Sciences of the United States of America, 2012
- β2 adrenergic activation induces the expression of IL-18 binding protein, a potent inhibitor of isoproterenol induced cardiomyocyte hypertrophy in vitro and myocardial hypertrophy in vivoJournal of Molecular and Cellular Cardiology, 2012
- Disruption of Caveolae Blocks Ischemic Preconditioning-Mediated S-Nitrosylation of Mitochondrial ProteinsAntioxidants and Redox Signaling, 2012
- Cardiac Dysfunction and Noncardiac Dysfunction as Precursors of Heart Failure With Reduced and Preserved Ejection Fraction in the CommunityCirculation, 2011
- S-Nitrosylation Regulates Nuclear Translocation of Chloride Intracellular Channel Protein CLIC4Online Journal of Public Health Informatics, 2010
- S -Nitrosylation in Cardiovascular SignalingCirculation Research, 2010
- Protein S -Nitrosylation and CardioprotectionCirculation Research, 2010
- Role of AT1 receptor in isoproterenol-induced cardiac hypertrophy and oxidative stress in miceJournal of Molecular and Cellular Cardiology, 2007
- S-Nitrosylation: NO-Related Redox Signaling to Protect Against Oxidative StressAntioxidants and Redox Signaling, 2006